183 related articles for article (PubMed ID: 17703136)
1. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Tawara S; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Aug; 50(2):195-200. PubMed ID: 17703136
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
Abe K; Shimokawa H; Morikawa K; Uwatoku T; Oi K; Matsumoto Y; Hattori T; Nakashima Y; Kaibuchi K; Sueishi K; Takeshit A
Circ Res; 2004 Feb; 94(3):385-93. PubMed ID: 14670839
[TBL] [Abstract][Full Text] [Related]
3. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
Abe K; Tawara S; Oi K; Hizume T; Uwatoku T; Fukumoto Y; Kaibuchi K; Shimokawa H
J Cardiovasc Pharmacol; 2006 Dec; 48(6):280-5. PubMed ID: 17204906
[TBL] [Abstract][Full Text] [Related]
4. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.
Elias-Al-Mamun M; Satoh K; Tanaka S; Shimizu T; Nergui S; Miyata S; Fukumoto Y; Shimokawa H
Circ J; 2014; 78(4):967-76. PubMed ID: 24553194
[TBL] [Abstract][Full Text] [Related]
6. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
Akagi S; Nakamura K; Matsubara H; Kondo M; Miura D; Matoba T; Egashira K; Ito H
J Cardiovasc Pharmacol; 2016 Apr; 67(4):290-8. PubMed ID: 26745002
[TBL] [Abstract][Full Text] [Related]
7. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
8. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
[TBL] [Abstract][Full Text] [Related]
9. DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Chen D; Yuan T; Chen Y; Zhang H; Niu Z; Fang L; Du G
Eur J Pharmacol; 2022 Mar; 919():174779. PubMed ID: 35092757
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
Li FH; Xia W; Li AW; Zhao CF; Sun RP
Chin Med J (Engl); 2007 Jan; 120(1):22-9. PubMed ID: 17254483
[TBL] [Abstract][Full Text] [Related]
11. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
12. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
14. Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.
Schwenke DO; Pearson JT; Sonobe T; Ishibashi-Ueda H; Shimouchi A; Kangawa K; Umetani K; Shirai M
J Appl Physiol (1985); 2011 Apr; 110(4):901-8. PubMed ID: 21212241
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Oka M; Homma N; Taraseviciene-Stewart L; Morris KG; Kraskauskas D; Burns N; Voelkel NF; McMurtry IF
Circ Res; 2007 Mar; 100(6):923-9. PubMed ID: 17332430
[TBL] [Abstract][Full Text] [Related]
16. A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats.
Ueno M; Miyauchi T; Sakai S; Yamauchi-Kohno R; Goto K; Yamaguchi I
J Am Coll Cardiol; 2002 Jul; 40(1):175-81. PubMed ID: 12103273
[TBL] [Abstract][Full Text] [Related]
17. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats.
Itoh T; Nagaya N; Fujii T; Iwase T; Nakanishi N; Hamada K; Kangawa K; Kimura H
Am J Respir Crit Care Med; 2004 Jan; 169(1):34-8. PubMed ID: 14525801
[TBL] [Abstract][Full Text] [Related]
18. Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension.
Abe K; Morikawa K; Hizume T; Uwatoku T; Oi K; Seto M; Ikegaki I; Asano T; Kaibuchi K; Shimokawa H
J Cardiovasc Pharmacol; 2005 Feb; 45(2):120-4. PubMed ID: 15654260
[TBL] [Abstract][Full Text] [Related]
19. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Gupta N; Rashid J; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
Mol Pharm; 2017 Mar; 14(3):830-841. PubMed ID: 28165252
[TBL] [Abstract][Full Text] [Related]
20. The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Jasińska-Stroschein M; Owczarek J; Łuczak A; Orszulak-Michalak D
Pharmacology; 2013; 91(3-4):178-84. PubMed ID: 23428587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
